Market growth in 2006 will slow down somewhat. I expect that we will be able to continue to gain market share.

I am pleased with the overall strong performance of our business in the third quarter, particularly the dynamic growth of Pharmaceuticals.

Our increased level of investment in marketing and sales, with the priority on key growth drivers, resulted in a sales growth of 21 percent in Pharmaceuticals in the U.S.,

We are confident of delivering in 2006 another year of dynamic growth with record sales and earnings.

Our plan is to turn around the Chiron vaccines business, which will require investments in R&D and manufacturing to increase quality and capacity,

At present, no collaboration has been discussed with Roche management, although we hope that over time we will be able to explore areas of collaboration.